Abuse-Deterrent Opioid Formulation with pH-Responsive Buffering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively deter abuse of opioid analgesics, as they do not adequately prevent misuse and minimize physical or psychological dependency, despite attempts to incorporate abuse-deterrent features in oral dosage forms.
Innovation Solution
A pharmaceutical composition comprising a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component, which includes a core, a shell, and a subcoat, along with an ingredient to increase gastric emptying time or decrease gastric acid production, to regulate drug release and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid analgesics are administered to treat pain, then therapeutic efficacy is improved, but abuse potential and risk of dependency increase
Solution Approach 1:
The patent segments the drug delivery system into multiple functional layers: an inner core containing the opioid analgesic, a middle buffering layer that neutralizes gastric acid, and an outer enteric coating that provides abuse-deterrent properties. This segmentation allows the drug to maintain therapeutic efficacy while preventing abuse through controlled release mechanisms and unpleasant taste upon crushing.
Solution Approach 2:
The patent introduces buffering ingredients (such as calcium carbonate, magnesium oxide, or aluminum hydroxide) as intermediaries between the opioid analgesic and the gastric environment. These buffering agents neutralize gastric acid to create a pH environment that prevents premature drug release and reduces abuse potential, while still allowing controlled absorption at the intended dosage.
2Object-affected harmful factors
If buffering ingredients are added to neutralize gastric acid and control drug release, then abuse deterrence is improved, but gastric emptying time may be prolonged excessively
Solution Approach 1:
The patent employs dynamic pH-responsive release mechanisms where the buffering layer gradually neutralizes gastric acid over time, and the enteric coating dynamically responds to pH changes in the gastrointestinal tract. This dynamic system controls drug release based on the local environment, preventing premature release while avoiding excessive prolongation of gastric emptying time.
Solution Approach 2:
The patent utilizes pH parameter changes in the gastrointestinal tract to control drug release. The buffering ingredients raise the local pH environment, and the enteric coating is designed to dissolve or become permeable at specific pH thresholds, thereby controlling the timing and rate of drug release without excessively prolonging gastric emptying time.
3Object-affected harmful factors
If enteric coating is applied to delay drug release and prevent abuse, then abuse potential is reduced, but therapeutic onset may be delayed
Solution Approach 1:
The patent applies preliminary action by pre-coating the drug core with buffering layers and enteric materials before administration. This preliminary structure is designed to withstand gastric conditions and release the drug at the appropriate location and time, ensuring both abuse deterrence and timely therapeutic onset without requiring post-administration adjustments.
Solution Approach 2:
The patent replaces mechanical abuse-deterrent features (such as physical barriers or complex delivery systems) with chemically-based controlled release mechanisms using pH-responsive enteric coatings and buffering layers. This substitution maintains therapeutic onset speed while providing effective abuse deterrence through chemical rather than mechanical means.
Data Source
AI summary
An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.